Syantra Plans Summer Launch Of Onco-ID
Calgary startup Syantra plans to launch Onco-ID, a blood-based breast cancer screening test, in select Canada, US and Europe locations this summer, and will publish updated clinical-trial data around May. Onco-ID uses machine learning to detect immune-response gene-expression biomarker patterns rather than ctDNA, aiming to improve early detection—particularly for women with dense breasts—and target reimbursement at roughly $350–$500 per test.
Key Points
- 1Develops Onco-ID blood test detecting immune-response gene-expression biomarkers for early breast cancer.
- 2Highlights mammography limits in dense breasts and aims to detect cancer before ctDNA is present.
- 3Enables clinicians and payers to consider non-invasive, lower-cost screening with planned summer early-access rollout.
Scoring Rationale
High practical and commercial relevance with credible funding and trials, but limited peer-reviewed validation and company-led evidence.
Sources
Public references used for this report.
Practice interview problems based on real data
1,625 SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problems
